


Supplementary information

**Choosing drugs for UK
COVID-19 treatment trials**

In the format provided by the authors



Supplementary Figure 1 | **Drug prioritization into the UK clinical trials platforms and the UK Covid 19 therapeutics advisory panel (UK-CTAP).** Following nomination through the open online portal, the independent due diligence team established the knowledge base for a given candidate, specialist subgroups then contextualized that knowledge with expert opinion, and UK-CTAP considered all of the information to create a balanced portfolio. The due diligence team included clinical pharmacology, immunology, virology, and regulatory expertise, and in-house pharmacokinetic and pharmacodynamic modelling. The team was assembled through rapid secondments from universities, the NHS, regulatory authorities and the private sector within a matter of weeks. Data were gathered from diverse data sources including published literature, pre-prints, international databases, and through international links with the US National Institutes for Health, Wellcome, the European Clinical Research Infrastructure Network and the World Health Organisation.



Supplementary Figure 2 | Summary of the work of the UK Covid 19 therapeutics advisory panel (UK-CTAP).